Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Oncology InstituteTOIIW 60 Earnings per Share (Diluted) is $0.00 as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 60/100. The stock has 4 warning signs investors should review. Among 509 Healthcare Providers & Services companies, The Oncology Institute ranks better than 65.82% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 24.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -9.60% per year.
During the past 8 years, The Oncology Institute's highest 3-Year average EPS without NRI Growth Rate was 24.70% per year. The lowest was -148.40% per year. And the median was -26.55% per year.
The Oncology Institute (NAS:TOIIW) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
The Oncology Institute Earnings per Share (Diluted) Related Terms
The Oncology Institute Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for The Oncology Institute's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute Earnings per Share (Diluted) Chart
TOIIW vs CYH, SRTA, CCRN: Earnings per Share (Diluted) Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's PE Ratio distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's PE Ratio falls into.
The Oncology Institute Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
The Oncology Institute's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.00 mean?
The Oncology Institute (TOIIW) has a Earnings per Share (Diluted) of $0.00 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #174 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 34.2%.
Is The Oncology Institute's Earnings per Share (Diluted) too high?
The Oncology Institute's current Earnings per Share (Diluted) is $0.00. Based on the distribution chart, The Oncology Institute ranks #174 out of 509 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, The Oncology Institute has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Earnings per Share (Diluted) compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #174 out of 509 companies for Earnings per Share (Diluted). This puts The Oncology Institute in the upper half of its industry. The industry median Earnings per Share (Diluted) is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Healthcare Providers & Services company?
The median Earnings per Share (Diluted) among Healthcare Providers & Services companies is 11.70, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median Earnings per Share (Diluted) is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current Earnings per Share (Diluted) is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Earnings per Share (Diluted) of $0.00. The current Earnings per Share (Diluted) is $0.00. The Oncology Institute's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Earnings per Share (Diluted) is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
60GF Score
Get the complete analysis for TOIIW
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 
